![Utilizing the latest data from ESMO 2020 to optimize the management of patients with HR+/HER2- breast cancer Utilizing the latest data from ESMO 2020 to optimize the management of patients with HR+/HER2- breast cancer](https://touchoncology.com/wp-content/uploads/sites/2/2020/12/5.png)
Utilizing the latest data from ESMO 2020 to optimize the management of patients with HR+/HER2- breast cancer
![Twitter 上的 ESMO - Eur. Oncology:"#ESMO22: The innovative, LIVE Plus format will offer participants the chance to attend in Paris or online through a virtual format. 📣 Abstract submission system now open. Twitter 上的 ESMO - Eur. Oncology:"#ESMO22: The innovative, LIVE Plus format will offer participants the chance to attend in Paris or online through a virtual format. 📣 Abstract submission system now open.](https://pbs.twimg.com/media/FLV09NmXwAIG2i9.jpg:large)
Twitter 上的 ESMO - Eur. Oncology:"#ESMO22: The innovative, LIVE Plus format will offer participants the chance to attend in Paris or online through a virtual format. 📣 Abstract submission system now open.
![Utilizing the latest data from ESMO 2020 to optimize the management of patients with HR+/HER2- breast cancer Utilizing the latest data from ESMO 2020 to optimize the management of patients with HR+/HER2- breast cancer](https://touchoncology.com/wp-content/uploads/sites/2/2020/12/3.png)